Corcept says EU CHMP backs Lifyorli combo for platinum — resistant ovarian cancer

EU drug regulator’s CHMP backed marketing authorization for Corcept’s Lifyorli (relacorilant) with nab-paclitaxel in platinum-resistant ovarian cancer. Recommendation cited Phase 2 and Phase 3 ROSELLA data showing longer progression-free survival and overall survival versus nab-paclitaxel alone. European Commission decision expected in Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via (Ref. ID: 202609180800BIZWIRE_USPR_____20260918_BW490790) on September 18, 2026, and is solely responsible for the information contained therein. (C)